Drugs / EpiCeram
Trials 2 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT03663673 | Sep 2018 → Jul 2019 | atopic eczema | Stanford University | Completed | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT03742414 | Jun 2021 → May 2028 expected | atopic eczema | Kari Nadeau, MD, PhD | Active not recruiting | No outcome recorded |
Also used as a comparator or background therapy in 2 trials
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 31 trial | ||||||
| Phase 3 | NCT03667651 Comparator | Mar 2018 → May 2027 expected | asthma, atopic eczema, food allergy | University of Melbourne | Active not recruiting | No outcome recorded |
| Phase 41 trial | ||||||
| Phase 4 | NCT01093469 Comparator | Sep → Dec 2009 | atopic eczema | Wake Forest University Health Sciences | Completed | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 4 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | EpiCeram | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01093469 ↗ |
| Route | Topical | “skin treated with EpiCeram®, Aveeno Daily Moisturising Sheer Hydration Lotion®” NCT03663673 ↗ |